Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
Submitted by
admin
on July 13, 2018 - 11:55am
Source:
CP Wire
News Tags:
AB928
Arcus Biosciences
Taiho Pharmaceutical
oncology
Asia
Japan
Headline:
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
snippet:
Total development agreement could be worth up to $275 million
AB928 has the potential to reverse adenosine-induced immune suppression within the tumor microenvironment
Do Not Allow Advertisers to Use My Personal information
